A Phase 1/2 Study to Evaluate the Safety and Efficacy of ARV-766 Given by Mouth in Men with Metastatic Castration-Resistant Prostate Cancer who Have Progressed on Prior Approved Systemic Therapies
Part A and B: Histological, pathological, or cytological confirmed diagnosis of adenocarcinoma of the prostate.
Progressive mCRPC. Ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration). Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Part A: Progression on at least 2 prior approved systemic therapies for metastatic prostate cancer (at least one must be a second-generation androgen inhibitor, e.g., abiraterone, enzalutamide, darolutamide, apalutamide).
Part B: Participants must have received at least one but no more than three prior second generation anti-androgen agents (e.g., enzalutamide or abiraterone). Participants must have received no more than two prior chemotherapy regimens.
Part A and B: Known symptomatic brain metastases requiring steroids (above physiologic replacement doses).
Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease, or previous gastric resection or lap band surgery. Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow.
Receipt of an investigational drug(s) within 4 weeks prior to anticipated first dose. Systemic anti-cancer therapy within 2 weeks of first dose of study drug (except agents to maintain castrate status). For bicalutamide, mitomycin C, or nitrosoureas the exclusion period must be 6 weeks and for abiraterone 4 weeks.
Learn More at ClinicalTrials.gov